NFKB1 and breast carcinoma: It remains therefore unclear whether upregulation of NF-κB signaling aids to sensitize cells to Bortezomib or increases drug resistance in breast cancer and whether hsa-let-7a-5p increases Bortezomib sensitivity via downregulation of NKIRAS2 and TNFAIP3.